Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harold Bernstein

Glaucoma Specialist Norfolk, VA Medical Doctor

NPI 1215921994 CMS profile 9220

6160 Kempsville Cir Ste 120B, Norfolk, VA 23502

Open in the dashboard

General payments

$6,796

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harold Bernstein of Norfolk, VA is reported in the CMS Open Payments database as having received $6,796 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Glaucoma Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,477 23
2024 General $1,161 13
2023 General $644 19
2022 General $824 24
2021 General $474 18
2020 General $1,603 20
2019 General $613 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harold Bernstein
  • Glaucoma Specialist median
  • Middle half of Glaucoma Specialist
  • National median

In program year 2025, general payments to Harold Bernstein were reported at $1,477. Among 370 Glaucoma Specialist profiles paid that year, the median was $597 and the middle half received between $244 and $1,607.

Show as a table
Year Harold Bernstein Glaucoma Specialist median Middle half National median
2019 $613 $433 $150–$1,170 $163
2020 $1,603 $242 $74–$693 $114
2021 $474 $324 $122–$936 $132
2022 $824 $399 $121–$1,081 $149
2023 $644 $458 $190–$1,208 $160
2024 $1,161 $558 $215–$1,359 $164
2025 $1,477 $597 $244–$1,607 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerie Pharmaceuticals, Inc. $1,261 21 payments
  2. Alcon Vision LLC $1,253 25 payments
  3. Glaukos Corporation $842 6 payments
  4. AbbVie, Inc. $763 25 payments
  5. New World Medical,Inc. $737 6 payments
  6. Allergan Inc. $470 11 payments
  7. Sight Sciences, Inc. $244 7 payments
  8. Bausch & Lomb, a division of Bausch Health US, LLC $231 12 payments
  9. Sun Pharmaceutical Industries Inc. $217 10 payments
  10. Bausch & Lomb Americas Inc. $153 3 payments
  11. Other $625 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,876 145 payments
  2. Consulting Fee $820 1 payment
  3. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. rocklatan $1,137 15 payments
  2. rhopressa $908 9 payments
  3. Ahmed Glaucoma Valve $555 3 payments
  4. Kahook Dual Blade $555 3 payments
  5. XEN GLAUCOMA TREATMENT SYSTEM $537 9 payments
  6. iDose $470 3 payments
  7. HYDRUS Microstent $376 3 payments
  8. DURYSTA $356 14 payments
  9. Clareon $304 5 payments
  10. Clearpath $283 1 payment
  11. Other $4,064 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,718

Median for Ophthalmology: 891

Drug cost

$209,615

Median for Ophthalmology: $68,233

Branded share of claims

29.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 155 $78,477
Combigan Brimonidine Tartrate/Timolol Brand 38 $15,084
Travoprost Generic 72 $13,628
Rhopressa Netarsudil Mesylate Brand 29 $12,932
Rocklatan Netarsudil Mesylat/Latanoprost Brand 29 $12,267
Simbrinza Brinzolamide/Brimonidine Tart Brand 41 $12,131
Prednisolone Acetate Generic 224 $8,648
Latanoprost Generic 807 $7,542
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 414 $6,653
Vyzulta Latanoprostene Bunod Brand 21 $6,425

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$160,723

Medicare's payments for the services billed

Medicare patients

459

Average age 77

Services billed

2,246

251 women, 208 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 34%
Chronic kidney disease 23%
Ischemic heart disease 21%
Atrial fibrillation 19%
Osteoporosis 16%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Glaucoma Specialist in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record